Is there still a role for stem cell transplantation in multiple myeloma?

被引：24

作者：

Mina, Roberto ^{[1
]}

Lonial, Sagar ^{[1
]}

机构：

[1] Emory Univ, Hematol & Med Oncol, Winship Canc Inst, 1365 Clifton Rd, Atlanta, GA 30322 USA

来源：

CANCER | 2019年 / 125卷 / 15期

关键词：

allogeneic; autologous; multiple myeloma; novel agents; transplant; TERM-FOLLOW-UP; PROSPECTIVE RANDOMIZED-TRIAL; BONE-MARROW-TRANSPLANTATION; HIGH-RISK CYTOGENETICS; HIGH-DOSE CHEMOTHERAPY; AUTOLOGOUS TRANSPLANTATION; STANDARD CHEMOTHERAPY; MAINTENANCE THERAPY; ELDERLY-PATIENTS; FRONT-LINE;

D O I：

10.1002/cncr.32060

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

High-dose chemotherapy and autologous stem cell transplantation (ASCT) are a standard of care for transplant-eligible patients with newly diagnosed multiple myeloma (MM). The introduction of novel agents, which range from immunomodulatory drugs and proteasome inhibitors to monoclonal antibodies and have now been integrated into both induction and salvage regimens, has dramatically revolutionized the treatment landscape of MM and challenged the role of high-dose chemotherapy and ASCT in treating MM. These advances have led to a number of provocative questions. First, what is the current role of stem cell transplantation (SCT) in comparison with standard-dose therapy incorporating novel agents? Second, should ASCT be performed upfront ("early") or later ("delayed") in the course of the disease? Third, should single or double ASCT be performed? Fourth, is allogeneic SCT still an option for patients with MM? This article provides an overview of available data and evidence-based responses regarding the role of SCT in MM.

引用

页码：2534 / 2543

页数：10

共 67 条

[61] Hematopoietic Stem Cell Transplantation for Multiple Myeloma: Guidelines from the American Society for Blood and Marrow Transplantation [J].

Shah, Nina ;

Callander, Natalie ;

Ganguly, Siddhartha ;

Gul, Zartash ;

Hamadani, Mehdi ;

Costa, Luciano ;

Sengsayadeth, Salyka ;

Abidi, Muneer ;

Hari, Parameswaran ;

Mohty, Mohamad ;

Chen, Yi-Bin ;

Koreth, John ;

Landau, Heather ;

Lazarus, Hillard ;

Leather, Helen ;

Majhail, Navneet ;

Nath, Rajneesh ;

Osman, Keren ;

Perales, Miguel-Angel ;

Schriber, Jeffrey ;

Shaughnessy, Paul ;

Vesole, David ;

Vij, Ravi ;

Wingard, John ;

Giralt, Sergio ;

Savani, Bipin N. .

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2015, 21 (07) :1155-1166

[62] Allogeneic hematopoietic cell transplantation for multiple myeloma in Europe: trends and outcomes over 25 years. A study by the EBMT Chronic Malignancies Working Party [J].

Sobh, M. ;

Michallet, M. ;

Gahrton, G. ;

Iacobelli, S. ;

van Biezen, A. ;

Schoenland, S. ;

Petersen, E. ;

Schaap, N. ;

Bonifazi, F. ;

Volin, L. ;

Meijer, E. ;

Niederwieser, D. ;

El-Cheikh, J. ;

Tabrizi, R. ;

Fegeux, N. ;

Finke, J. ;

Bunjes, D. ;

Cornelissen, J. ;

Einsele, H. ;

Bruno, B. ;

Potter, M. ;

Fanin, R. ;

Mohty, M. ;

Garderet, L. ;

Kroeger, N. .

LEUKEMIA, 2016, 30 (10) :2047-2054

[63] Intermediate-dose melphalan compared with myeloablative treatment in multiple myeloma: long-term follow-up of the Dutch Cooperative Group HOVON 24 trial [J].

Sonneveld, Pieter ;

van der Holt, Bronno ;

Segeren, Christine M. ;

Vellenga, Edo ;

Croockewit, Alexandra J. ;

Verhoe, Gregor E. G. ;

Cornelissen, Jan J. ;

Schaafsma, Martijn R. ;

van Oers, Marinus H. J. ;

Wijermans, Pierre W. ;

Westveer, Petra H. M. ;

Lokhorst, Henk M. .

HAEMATOLOGICA, 2007, 92 (07) :928-935

[64] Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group [J].

Sonneveld, Pieter ;

Avet-Loiseau, Herve ;

Lonial, Sagar ;

Usmani, Saad ;

Siegel, David ;

Anderson, Kenneth C. ;

Chng, Wee-Joo ;

Moreau, Philippe ;

Attal, Michel ;

Kyle, Robert A. ;

Caers, Jo ;

Hillengass, Jens ;

San Miguel, Jesus ;

van de Donk, Niels W. C. J. ;

Einsele, Hermann ;

Blade, Joan ;

Durie, Brian G. M. ;

Goldschmidt, Hartmut ;

Mateos, Maria-Victoria ;

Palumbo, Antonio ;

Orlowski, Robert .

BLOOD, 2016, 127 (24) :2955-2962

[65]

Stadtmauer EA, 2016, BLOOD, V128

[66] Autotransplant with and without induction chemotherapy in older multiple myeloma patients: long-term outcome of a randomized trial [J].

Straka, Christian ;

Liebisch, Peter ;

Salwender, Hans ;

Hennemann, Burkhard ;

Metzner, Bernd ;

Knop, Stefan ;

Adler-Reichel, Sigrid ;

Gerecke, Christian ;

Wandt, Hannes ;

Bentz, Martin ;

Bruemmendorf, Tim Hendrik ;

Hentrich, Marcus ;

Pfreundschuh, Michael ;

Wolf, Hans-Heinrich ;

Sezer, Orhan ;

Bargou, Ralf ;

Jung, Wolfram ;

Truemper, Lorenz ;

Hertenstein, Bernd ;

Heidemann, Else ;

Bernhard, Helga ;

Lang, Nicola ;

Frickhofen, Norbert ;

Hebart, Holger ;

Schmidmaier, Ralf ;

Sandermann, Andreas ;

Dechow, Tobias ;

Reichle, Albrecht ;

Schnabel, Brigitte ;

Schaefer-Eckart, Kerstin ;

Langer, Christian ;

Gramatzki, Martin ;

Hinke, Axel ;

Emmerich, Bertold ;

Einsele, Hermann .

HAEMATOLOGICA, 2016, 101 (11) :1398-1406

[67] Matched-pair analysis to compare the outcomes of a second salvage auto-SCT to systemic chemotherapy alone in patients with multiple myeloma who relapsed after front-line auto-SCT [J].

Yhim, H-Y ;

Kim, K. ;

Kim, J. S. ;

Kang, H. J. ;

Kim, J-A ;

Min, C-K ;

Bae, S. H. ;

Park, E. ;

Yang, D-H ;

Suh, C. ;

Kim, M. K. ;

Mun, Y-C ;

Eom, H. S. ;

Shin, H. J. ;

Yoon, H-J ;

Kwon, J. H. ;

Lee, J. H. ;

Kim, Y. S. ;

Yoon, S-S ;

Kwak, J-Y .

BONE MARROW TRANSPLANTATION, 2013, 48 (03) :425-432

← 1 2 3 4 5 6 7 →